Fledgling Gossamer sets up an early biotech IPO test for 2019 with a $265M challenge
Last summer when I was interviewing Faheem Hasnain about the $330 million he had raised in a snap for his new biotech upstart Gossamer, he happily noted that there was an IPO out there on the horizon.
Turns out, that time horizon was quite close.
On Friday Hasnain, executive chairman, and Gossamer CEO Sheila Gujrathi posted their S-1, outlining an IPO in search of roughly $265 million — though that’s a number they would no doubt like to surpass. It’s a fitting end for 2018, which saw a string of unicorns go public with little or no human data to their credit for startups with short takeoff trajectories on a flight path filled with peril.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
